Iktos enters into AI agreement with Merck KGaA, Darmstadt, Germany
Category: #business |   By Pankaj Singh |   Date: 2020-11-07

Iktos enters into AI agreement with Merck KGaA, Darmstadt, Germany

AI-specialized new drug design major, Iktos, has reportedly entered into an additional partnership agreement in artificial intelligence for new drug design with leading science and technology firm, Merck KGaA, Darmstadt, Germany. This agreement focuses on the utilization of Iktos’ novel generative design technology in a structure-enabled context for facilitating the cost-effective and rapid design of an unannounced Merck KGaA, Darmstadt, Germany drug discovery initiative.

As per the Global Head of Research for the Healthcare business, Merck KGaA, Darmstadt, Germany, Joern-Peter Halle, AI possesses the potential for the acceleration and improvement of drug discovery process, implying faster access to novel treatment alternatives for patients. This additional partnership is a demonstration of the company’s commitment to collaborations for the purpose of accessing the latest technology to enrich the company’s discovery engine, added Halle.

In the past three years, Iktos has successfully emerged as a global leader in artificial intelligence for drug design. The company was reportedly the first AI major to publish an experimental certification of the generative artificial intelligence technology for MPO in a real-life drug discovery project in 2018, since which the firm has entered into agreements with biopharmaceutical companies.

As per sources, Iktos markets its AI technology both as software products and as services. The company’s Makya, generative AI SaaS software, has already been delivered to numerous customers, and its retro-synthesis AI SaaS platform, Spaya, is presently being deployed as a custom version with the firm’s IT infrastructure.

Iktos’ AI technology, helps in bringing efficiency and speed to the drug discovery process, via automatic designing of virtual novel molecules having desired activities for the treatment of a given disease. This is speculated to address one of the prominent issues in drug design, pertaining to the quick identification of molecules that simultaneously meet various drug-like and bioactivity criteria related to drug development and discovery.

 

Source Credits:

https://www.businesswire.com/news/home/20201105005068/en/Iktos-Announces-Additional-Collaboration-With-Merck-KGaA-Darmstadt-Germany-in-AI-for-New-Drug-Design

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh     Twitter

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with Read more...

More News By Pankaj Singh

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

By Pankaj Singh

Airwaive and Shaurrya Teleservices (STS) has reportedly announced an international strategic collaboration to jointly build 5G wireless network service in India, assisting telecom providers in advancing 5G technology throughout the nation. Notably...

Valneva looking to capitalize on growing prevalence of Lyme disease

Valneva looking to capitalize on growing prevalence of Lyme disease

By Pankaj Singh

French drugmaker Valneva SE is now reportedly betting on its vaccine VLA15 for treating climate change-induced Lyme disease, as it looks to capitalize on growing prevalence of tick-borne illnesses following the disappointing sales of its COVID-19 vac...

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

By Pankaj Singh

Reliance Jio Infocomm Ltd., owned by billionaire industrialist Mukesh Ambani, was found to be the most aggressive participant in the government-backed 5G auction in India where several telecom behemoths agreed to invest at least USD 19 billion. Jio w...